Zimmer Biomet (ZBH) Q2 2026 earnings review
Sales Transformation Yields Early Wins; Guidance Raised
Zimmer Biomet delivered a strong Q2, brushing off fears of an extended U.S. sales force disruption. Organic constant currency revenue growth accelerated to 4.0%, prompting management to raise full-year top and bottom-line guidance. While the aggressive commercial transition and Paragon 28 integration are visibly weighing on profitability—Adjusted EPS was flat YoY and operating margins compressed—the top-line momentum proves the strategy is working. Surging demand for Technology & Data (+21.5%) offset alarming stagnation in the core Knees segment (+0.1%).
🐂 Bull Case
The massive U.S. sales channel transition was supposed to crush 2026 growth (initially guided 1-3%). Instead, Q2 accelerated to 4.0% and FY guidance was raised. The transition is driving rapid productivity gains rather than widespread account losses.
The Technology & Data segment grew a massive 21.5% organically. Strong capital placements of ROSA and early traction of new innovations (like the ROSA Shoulder System) create a captive funnel for future high-margin implant pull-through.
🐻 Bear Case
The core Knees business is significantly lagging the company, growing a measly 0.1% organically. International Knee sales are actually reversing, down 1.5% YoY. The company is likely bleeding market share to competitors in this vital category.
The top-line beat did not fall to the bottom line. Adjusted EPS of $2.07 was entirely flat YoY. Adjusted operating margin compressed from 27.8% a year ago to 25.7%, as the costs of the sales force transition and M&A dilution take their toll.
⚖️ Verdict: 🟢
Bullish. The primary risk hanging over Zimmer Biomet in 2026 was the execution of its U.S. sales force overhaul. Raising organic growth guidance midway through the year indicates management has a firm grip on the transition. The margin compression is a known, expected cost of this transformation.
Key Themes
Technology & Data Surging
This segment was the absolute standout, accelerating to 21.5% organic constant currency growth (up from 14.6% in Q1). Zimmer Biomet is successfully placing capital equipment, heavily supported by the ROSA robotics platform. The recent FDA clearance and first cases of the next-generation ROSA Shoulder System—the first to support both glenoid and humeral bone preparation—will likely sustain this momentum.
Hips Providing Reliable Baseline Growth
While Knees struggle, Hips remain stable and strong. The segment delivered 5.1% organic constant currency growth in Q2. U.S. growth was particularly robust at 5.9%, driven by the continued success of the 'triple play' portfolio (Avenir, OrthoGrid, HAMMR) converting competitive accounts.
Healthy Underlying Markets
Management explicitly cited 'healthy underlying markets' as a key factor enabling the guidance raise. The broader orthopedic market continues to grow reliably north of 4%, supported by demographic trends and persistent post-COVID patient backlogs, providing a forgiving macro backdrop for Zimmer's internal transition.
Knees Segment is a Glaring Weakness
The Knees segment continues to be Zimmer Biomet's primary laggard. Total Knees organic growth decelerated to a near-standstill at +0.1%. The U.S. managed just 1.4% growth, while International Knees reversed into negative territory (-1.5%). Despite the rollout of Persona OsseoTi, the company appears to be ceding market share to competitors in its largest product category.
Margin Compression is Severe
The aggressive transition of 1099 sales agents to direct reps, combined with the integration of Paragon 28, is eating into profitability. Adjusted operating margin dropped from 27.8% in 25Q2 to approximately 25.7% in 26Q2. Adjusted EPS remained flat at $2.07 despite $100 million in additional revenue, indicating that incremental sales are currently coming at a significantly lower margin.
Capital Returns Prioritized Over M&A
After a string of acquisitions (Paragon 28, Monogram, OrthoGrid), management is leaning heavily into capital returns while they integrate. The company recently announced an increase in its share repurchase expectations to up to $1 billion for fiscal 2026 (up from the $750M guided in Q1), supporting EPS while the P&L absorbs commercial investments.
Other KPIs
Accelerating. Organic constant currency growth came in at 3.4%, a step up from the 1.6% seen in Q1. Reported growth was materially higher at 6.4%, reflecting the inorganic contribution of the Paragon 28 acquisition in the foot and ankle space.
Cash generation remains healthy. Operating cash flow of $447.9 million adequately covered strategic investments and allowed for continued aggressive share repurchases under the expanded $1 billion program.
Guidance
Accelerating. This is a massive shift in narrative. The company entered 2026 guiding to a depressed 1.0% - 3.0% range due to the expected disruption of firing independent sales reps and hiring direct ones. Raising the floor by 125 basis points mid-year signals the disruption phase is largely behind them.
Accelerating. Raised from the prior $8.40 - $8.55. The midpoint of $8.53 implies roughly 4% growth over FY25's $8.20. While modest, the raise is impressive given it absorbs heavy structural transition costs, lower gross margins, and the dilutive effect of the Paragon 28 acquisition.
Accelerating. Raised from 2.5% - 4.5%. This includes a ~110 bps expected inorganic contribution from Paragon 28 and a 50 bps tailwind from foreign exchange.
Key Questions
Knees Segment Strategy
International Knees reversed to -1.5% growth and U.S. Knees barely grew at 1.4%. Is this purely a lingering effect of legacy brand (NextGen) phase-outs, or are we structurally losing competitive ground? When will the Persona product cycle definitively re-accelerate this segment?
Margin Trajectory Exiting 2026
Adjusted operating margins fell roughly 200 basis points YoY in Q2. As the sales force transition moves past the halfway mark, what is the exact quarter we should expect margins to trough and begin expanding again?
ROSA Shoulder Rollout
With the ROSA Shoulder System now FDA cleared and seeing its first cases, what are the capital placement expectations for the back half of the year, and how quickly do you expect it to pull through S.E.T. implant volume?